Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. (ORKA) reported insider transactions by Chief Operating Officer Laura Lee Sandler on September 1, 2026. Sandler exercised 5,000 Employee Warrants at an exercise price of $7.80 per share into common stock, then sold 5,000 common shares in two open‑market transactions at weighted average prices around $91–$92 per share. Following the warrant exercise, Sandler held 74,996 Employee Warrants directly. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
Oruka Therapeutics, Inc. (ORKA) reported that Chief Executive Officer and director Lawrence Otto Klein exercised an employee warrant to acquire 75,000 shares of common stock at an exercise price of $7.80 per share and on the same date sold 75,000 shares of common stock in multiple open-market transactions. The sales, totaling 6,604, 63,596 and 4,800 shares, were executed at weighted average prices of $90.79, $91.90 and $92.44 per share, respectively, under a Rule 10b5-1 trading plan entered into on May 14, 2026. Following the exercise, Klein continued to hold 1,553,513 employee warrant shares, which expire on July 14, 2034.
Oruka Therapeutics, Inc. (ORKA) has a notice of proposed sale of securities filed under Rule 144 by officer Laura Sandler. The notice covers the planned resale of 5,000 shares of common stock on or after 09/01/2026 on NASDAQ, to be delivered through exercise of stock options for cash. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker.
The filing also lists prior sales of Oruka common stock for Sandler during the past three months, including 5,000 shares sold on 07/01/2026 and 600 shares sold on 06/15/2026.
Oruka Therapeutics, Inc. (ORKA) received a notice that Lawrence Klein intends to sell Oruka common stock under Rule 144. The planned transaction involves up to 75,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 09/01/2026, with the shares to be acquired via exercise of stock options for cash. The notice also reports that Klein sold 1,729 shares of Oruka common stock on 06/15/2026 during the prior three months.
Oruka Therapeutics, Inc. (ORKA) has established an “at the market offering” program to sell up to $500,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent or principal under a Form S-3 shelf registration. Sales may be made from time to time on Nasdaq or other markets at prevailing market prices or in negotiated/block trades.
TD Cowen will receive up to 3.0% of the gross sales price as commission and will be deemed an underwriter. Assuming all shares are sold at $104.86 per share, Oruka would issue about 4,768,262 shares, increasing shares outstanding from 61,069,887 to up to 65,838,149. The company plans to use net proceeds for general corporate purposes, including research and development and working capital, and does not expect to pay cash dividends in the foreseeable future.
As of June 30, 2026, historical net tangible book value was $18.25 per share$24.29, implying illustrative dilution of $80.57 per share to new investors purchasing at $104.86. The filing highlights risks including broad discretion over use of proceeds, potential future dilution from additional equity and convertible securities, and share price pressure from significant or perceived future sales.
Oruka Therapeutics, Inc. (ORKA) reported that Chief Commercial Officer Larry Todd Edwards received equity awards on August 24, 2026. He was granted 100,000 shares of Common Stock and an option to purchase 20,000 shares of Common Stock at an exercise price of $102.42 per share, both held directly.
The 100,000-share stock grant vests as to one-quarter on September 14, 2027, with the remaining three-quarters vesting in 12 equal quarterly installments thereafter. The 20,000-share option vests as to one-quarter of the underlying shares on August 24, 2027 and then 1/48 of the underlying shares monthly thereafter, and expires on August 23, 2036. The filing does not indicate use of a Rule 10b5-1 trading plan.
Oruka Therapeutics, Inc. (ORKA) filed an initial statement of beneficial ownership (Form 3) for Larry Todd Edwards, who serves as Chief Commercial Officer. The filing lists him as an officer of the company and does not report any specific equity transactions or detailed holdings in this data.
Oruka Therapeutics, Inc. (ORKA) appointed Todd Edwards as Chief Commercial Officer, effective August 24, 2026, under a July 22, 2026 letter agreement. Edwards is a veteran commercial leader from Arcutis Biotherapeutics, Incyte, UCB, AbbVie and TAP, with extensive experience in dermatology and immunology franchises.
His compensation includes a $525,000 annualized base salary, a discretionary annual bonus targeted at 40% of base salary, a stock option for 20,000 shares and 100,000 RSUs, plus a $200,000 signing bonus. If terminated without cause or he resigns for good reason, he is eligible for 12 months of salary and up to 12 months of company-paid health coverage, with enhanced cash and full equity acceleration upon qualifying terminations around a change in control.
Oruka Therapeutics, Inc. (ORKA) filed a shelf registration to offer and sell up to $1,000,000,000 of common stock, preferred stock, depositary shares and warrants from time to time, with specific terms to be set in future prospectus supplements. Within this, Oruka established a sales agreement with TD Securities (USA) LLC (TD Cowen) allowing an “at the market offering” of up to $500,000,000 of common stock on Nasdaq or other markets, for which TD Cowen may receive up to a 3.0% commission.
As of June 30, 2026, Oruka had 61,069,887 common shares and 137,138 Series B Preferred shares outstanding, out of 545,000,000 authorized common and 5,000,000 authorized preferred. The company reports historical net tangible book value of $1,114.5 million, or $18.25 per share, and illustrates that a hypothetical full use of the ATM at $104.86 per share would increase net tangible book value to $24.29 per share, implying significant dilution to new investors.